Flagship projects
European consortia
The Hudecek Lab is currently part of three European consortia funded by the EU.
EU Project imSAVAR
Nonclinical mimicking of the immune system effects of immunomodulatory therapies. The imSAVAR project aims to deliver a range of tools that will enhance our ability to assess the efficacy and safety of immunomodulatory therapies.
We also plan to develop new biological markers for diagnosing and predicting immune-mediated safety issues, and explore ways of mitigating them. Please find out more about the initial challenge, our approach, and objectives, as well as the intended impact below.
Further information about the project
Funding
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL.
More information about the EU Project imSAVAR.
EU Project T2EVOLVE
The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR).
Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.
Further information about the project
Funding
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945393. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA.
Related publication
Katrin Mestermann , Marie Eichler, Markus Machwirth, Kati Kebbel, Ulrike Köhl, Hermann Einsele, Claudia Müller, Jörg Lehmann, Tamás Raskó, Felix Lundberg, Zsuzsanna Izsvák, Gerno Schmiedeknecht, Michael Hudecek (2020)
P108 Clinical-grade Manufacturing of ROR1 CAR T-cells using a Novel virus-free Protocol. In: The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706). Bone Marrow Transplantation volume 55, pages181–714(2020).
Go to publication
More information about the EU Project T2EVOLVE.
EU Project AIDPATH
AIDPATH aims to facilitate patients access to CAR T cell therapy by creating a fully automated CAR T cell manufacturing pipeline that can be placed in the hospital itself.
Further information about the project
Funding
AIDPATH grant (Horizon 2020)
Related publication
Fraunhofer-Institut für Produktionstechnologie IPT (2021)
Pressemitteilung. Individualisierte Krebstherapie dank künstlicher Intelligenz bald schneller und effektiver.
Go to press release
Clinical trials
EU Project CARAMBA
CARAMBA is a phase I/IIa clinical study targeting SF7.
Further information about the project
Funding
CARAMBA grant (Horizon 2020)
Related publication
Tea Gogishvili, Sophia Danhof, Sabrina Prommersberger, Julian Rydzek, Martin Schreder, Christian Brede, Hermann Einsele, Michael Hudecek (2017)
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 + normal lymphocytes.
Blood. 2017 Dec 28;130(26):2838-2847. doi: 10.1182/blood-2017-04-778423.
Go to publication
CARAMBA EU project: SLAMF7 CAR-T treatment of multiple myeloma
More information about the EU Project CARAMBA.
EU Project EURECART
EURE-CART project’s main object is to conduct a multicentre, first-in-man Phase I/IIa clinical trial to demonstrate the safety and the efficacy of CD44v6 CAR-T cell immunotherapy in acute myeloid leukaemia and multiple myeloma.
Further information about the project
Proof of concept initiative PoC
Proof of concept initiative PoC is a clinical phase I study targeting ROR1.
Further information about the project
Funding
Proof of concept initiative Helmholtz/Fraunhofer/Universitätsklinika
Related publications
Mestermann K, Eichler M, Machwirth M, Kebbel K, Köhl U, Einsele H, Müller C, Lehmann J, Raskó T, Lundberg F, Izsvák Z, Schmiedeknecht G, Hudecek M (2020)
P09.08 Clinical-grade manufacturing of ROR1 CAR T cells using a novel virus-free protocol. Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-ITOC7.108.
Go to publication
Mestermann K, Eichler M, Machwirth M, Kebbel K, Köhl U, Einsele H, Müller C, Lehmann J, Raskó T, Lundberg F, Izsvák Z, Schmiedeknecht G, Hudecek M(2020)
P108 Clinical-grade Manufacturing of ROR1 CAR T-cells using a Novel virus-free Protocol. In: The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706). Bone Marrow Transplantation volume 55, pages181–714.
Go to publication